Does the media prefer ONC or PRAX?

In the previous week, BeOne Medicines had 2 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 13 mentions for BeOne Medicines and 11 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 0.63 beat BeOne Medicines' score of 0.18 indicating that Praxis Precision Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Praxis Precision Medicines 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PRAX or BNTX?

In the previous week, Praxis Precision Medicines had 7 more articles in the media than BioNTech. MarketBeat recorded 11 mentions for Praxis Precision Medicines and 4 mentions for BioNTech. BioNTech's average media sentiment score of 1.23 beat Praxis Precision Medicines' score of 0.63 indicating that BioNTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ROIV or PRAX?

In the previous week, Praxis Precision Medicines had 3 more articles in the media than Roivant Sciences. MarketBeat recorded 11 mentions for Praxis Precision Medicines and 8 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.12 beat Praxis Precision Medicines' score of 0.63 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Praxis Precision Medicines 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PRAX or INSM?

In the previous week, Insmed had 9 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 20 mentions for Insmed and 11 mentions for Praxis Precision Medicines. Insmed's average media sentiment score of 0.89 beat Praxis Precision Medicines' score of 0.63 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 12 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MRNA or PRAX?

In the previous week, Moderna had 12 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 23 mentions for Moderna and 11 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 0.63 beat Moderna's score of 0.52 indicating that Praxis Precision Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 9 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Praxis Precision Medicines 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Praxis Precision Medicines (PRAX) Competitors

$327.79 -0.07 (-0.02%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$329.68 +1.89 (+0.58%)

As of 06/26/2026 07:39 PM Eastern

Compare

PRAX vs. ONC, BNTX, ROIV, INSM, and MRNA

Should you buy Praxis Precision Medicines stock or one of its competitors? MarketBeat compares Praxis Precision Medicines with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Praxis Precision Medicines include BeOne Medicines (ONC), BioNTech (BNTX), Roivant Sciences (ROIV), Insmed (INSM), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.

How does Praxis Precision Medicines compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Praxis Precision Medicines (NASDAQ:PRAX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by company insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

BeOne Medicines has a net margin of 8.94% compared to Praxis Precision Medicines' net margin of 0.00%. BeOne Medicines' return on equity of 12.06% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Praxis Precision Medicines	N/A	-43.02%	-40.22%

BeOne Medicines has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	5.75	$286.93M	$4.47	62.62
Praxis Precision Medicines	$8.55M	1,068.86	-$303.27M	-$13.37	N/A

In the previous week, BeOne Medicines had 2 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 13 mentions for BeOne Medicines and 11 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 0.63 beat BeOne Medicines' score of 0.18 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Praxis Precision Medicines	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

BeOne Medicines currently has a consensus price target of $390.00, indicating a potential upside of 39.34%. Praxis Precision Medicines has a consensus price target of $566.21, indicating a potential upside of 72.74%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, analysts clearly believe Praxis Precision Medicines is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	4 Strong Buy rating(s)	2.95

BeOne Medicines has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.71, meaning that its share price is 171% more volatile than the broader market.

Summary

BeOne Medicines beats Praxis Precision Medicines on 9 of the 17 factors compared between the two stocks.

How does Praxis Precision Medicines compare to BioNTech?

Praxis Precision Medicines (NASDAQ:PRAX) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by company insiders. Comparatively, 19.2% of BioNTech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Praxis Precision Medicines currently has a consensus target price of $566.21, suggesting a potential upside of 72.74%. BioNTech has a consensus target price of $129.56, suggesting a potential upside of 42.03%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, research analysts clearly believe Praxis Precision Medicines is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	4 Strong Buy rating(s)	2.95
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

Praxis Precision Medicines has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-43.02%	-40.22%
BioNTech	-44.39%	-5.30%	-4.62%

Praxis Precision Medicines has a beta of 2.71, meaning that its stock price is 171% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market.

In the previous week, Praxis Precision Medicines had 7 more articles in the media than BioNTech. MarketBeat recorded 11 mentions for Praxis Precision Medicines and 4 mentions for BioNTech. BioNTech's average media sentiment score of 1.23 beat Praxis Precision Medicines' score of 0.63 indicating that BioNTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Praxis Precision Medicines has higher earnings, but lower revenue than BioNTech. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	1,068.86	-$303.27M	-$13.37	N/A
BioNTech	$3.25B	7.11	-$1.29B	-$5.88	N/A

Summary

Praxis Precision Medicines beats BioNTech on 10 of the 17 factors compared between the two stocks.

How does Praxis Precision Medicines compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Praxis Precision Medicines (NASDAQ:PRAX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

In the previous week, Praxis Precision Medicines had 3 more articles in the media than Roivant Sciences. MarketBeat recorded 11 mentions for Praxis Precision Medicines and 8 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.12 beat Praxis Precision Medicines' score of 0.63 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Roivant Sciences has higher earnings, but lower revenue than Praxis Precision Medicines. Roivant Sciences is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	2,966.77	-$299.77M	-$0.60	N/A
Praxis Precision Medicines	$8.55M	1,068.86	-$303.27M	-$13.37	N/A

Roivant Sciences currently has a consensus target price of $33.59, indicating a potential downside of 1.41%. Praxis Precision Medicines has a consensus target price of $566.21, indicating a potential upside of 72.74%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, analysts clearly believe Praxis Precision Medicines is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	4 Strong Buy rating(s)	2.95

Roivant Sciences has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.71, suggesting that its stock price is 171% more volatile than the broader market.

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 10.8% of Roivant Sciences shares are owned by insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Praxis Precision Medicines has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Praxis Precision Medicines	N/A	-43.02%	-40.22%

Summary

Praxis Precision Medicines beats Roivant Sciences on 10 of the 17 factors compared between the two stocks.

How does Praxis Precision Medicines compare to Insmed?

Praxis Precision Medicines (NASDAQ:PRAX) and Insmed (NASDAQ:INSM) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Praxis Precision Medicines has a beta of 2.71, indicating that its stock price is 171% more volatile than the broader market. Comparatively, Insmed has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market.

Praxis Precision Medicines currently has a consensus target price of $566.21, suggesting a potential upside of 72.74%. Insmed has a consensus target price of $211.86, suggesting a potential upside of 104.94%. Given Insmed's stronger consensus rating and higher probable upside, analysts plainly believe Insmed is more favorable than Praxis Precision Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	4 Strong Buy rating(s)	2.95
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

67.8% of Praxis Precision Medicines shares are owned by institutional investors. 3.0% of Praxis Precision Medicines shares are owned by company insiders. Comparatively, 2.1% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Praxis Precision Medicines has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Praxis Precision Medicines' return on equity of -43.02% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-43.02%	-40.22%
Insmed	-144.44%	-130.11%	-51.57%

In the previous week, Insmed had 9 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 20 mentions for Insmed and 11 mentions for Praxis Precision Medicines. Insmed's average media sentiment score of 0.89 beat Praxis Precision Medicines' score of 0.63 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	12 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Praxis Precision Medicines has higher earnings, but lower revenue than Insmed. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	1,068.86	-$303.27M	-$13.37	N/A
Insmed	$606.42M	36.95	-$1.28B	-$5.75	N/A

Summary

Praxis Precision Medicines beats Insmed on 9 of the 17 factors compared between the two stocks.

How does Praxis Precision Medicines compare to Moderna?

Moderna (NASDAQ:MRNA) and Praxis Precision Medicines (NASDAQ:PRAX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

Praxis Precision Medicines has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Praxis Precision Medicines	N/A	-43.02%	-40.22%

Praxis Precision Medicines has lower revenue, but higher earnings than Moderna. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	13.73	-$2.82B	-$8.15	N/A
Praxis Precision Medicines	$8.55M	1,068.86	-$303.27M	-$13.37	N/A

Moderna has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.71, meaning that its stock price is 171% more volatile than the broader market.

Moderna presently has a consensus price target of $37.13, suggesting a potential downside of 44.80%. Praxis Precision Medicines has a consensus price target of $566.21, suggesting a potential upside of 72.74%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	4 Strong Buy rating(s)	2.95

In the previous week, Moderna had 12 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 23 mentions for Moderna and 11 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 0.63 beat Moderna's score of 0.52 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	9 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

75.3% of Moderna shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 10.8% of Moderna shares are held by insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Praxis Precision Medicines beats Moderna on 9 of the 17 factors compared between the two stocks.

Get Praxis Precision Medicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRAX vs. The Competition

Export

Metric	Praxis Precision Medicines	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.14B	$3.63B	$7.05B	$12.19B
Dividend Yield	N/A	2.21%	2.66%	6.23%
P/E Ratio	-24.52	21.56	26.13	24.16
Price / Sales	1,068.86	334.26	556.13	101.81
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	9.41	8.31	10.78	6.38
Net Income	-$303.27M	$23.92M	$3.58B	$337.00M
7 Day Performance	16.11%	3.42%	2.22%	0.10%
1 Month Performance	-7.04%	0.39%	-0.09%	-1.28%
1 Year Performance	662.30%	65.22%	34.39%	27.68%

Praxis Precision Medicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRAX Praxis Precision Medicines	3.5392 of 5 stars	$327.79 0.0%	$566.21 +72.7%	+662.3%	$9.14B	$8.55M	N/A	110	Insider Trade High Trading Volume
ONC BeOne Medicines	4.7788 of 5 stars	$268.20 +1.4%	$390.00 +45.4%	+16.0%	$29.02B	$5.34B	60.00	12,000	News Coverage Analyst Upgrade Insider Trade
BNTX BioNTech	4.268 of 5 stars	$90.80 +0.3%	$129.56 +42.7%	-14.5%	$22.90B	$3.25B	N/A	7,807	Positive News
ROIV Roivant Sciences	2.0349 of 5 stars	$30.03 0.0%	$33.59 +11.9%	+199.1%	$21.61B	$8.26M	N/A	860	Positive News Insider Trade
INSM Insmed	3.5583 of 5 stars	$97.46 -0.4%	$212.50 +118.0%	+3.9%	$21.21B	$606.42M	N/A	1,664	News Coverage Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRAX) was last updated on 6/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Praxis Precision Medicines (PRAX) Competitors

PRAX vs. ONC, BNTX, ROIV, INSM, and MRNA

How does Praxis Precision Medicines compare to BeOne Medicines?

Summary

How does Praxis Precision Medicines compare to BioNTech?

Summary

How does Praxis Precision Medicines compare to Roivant Sciences?

Summary

How does Praxis Precision Medicines compare to Insmed?

Summary

How does Praxis Precision Medicines compare to Moderna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRAX vs. The Competition

Praxis Precision Medicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Praxis Precision Medicines (PRAX) Competitors

PRAX vs. ONC, BNTX, ROIV, INSM, and MRNA

How does Praxis Precision Medicines compare to BeOne Medicines?

Do insiders & institutionals believe in ONC or PRAX?

Is ONC or PRAX more profitable?

Which has higher valuation & earnings, ONC or PRAX?

Does the media prefer ONC or PRAX?

Do analysts rate ONC or PRAX?

Which has more volatility & risk, ONC or PRAX?

Summary

How does Praxis Precision Medicines compare to BioNTech?

Do institutionals and insiders have more ownership in PRAX or BNTX?

Do analysts prefer PRAX or BNTX?

Is PRAX or BNTX more profitable?

Which has more volatility & risk, PRAX or BNTX?

Does the media favor PRAX or BNTX?

Which has stronger earnings & valuation, PRAX or BNTX?

Summary

How does Praxis Precision Medicines compare to Roivant Sciences?

Does the media refer more to ROIV or PRAX?

Which has higher valuation & earnings, ROIV or PRAX?

Do analysts rate ROIV or PRAX?

Which has more volatility and risk, ROIV or PRAX?

Do insiders and institutionals believe in ROIV or PRAX?

Is ROIV or PRAX more profitable?

Summary

How does Praxis Precision Medicines compare to Insmed?

Which has more risk and volatility, PRAX or INSM?

Do analysts recommend PRAX or INSM?

Do insiders & institutionals believe in PRAX or INSM?

Is PRAX or INSM more profitable?

Does the media favor PRAX or INSM?

Which has higher earnings & valuation, PRAX or INSM?

Summary

How does Praxis Precision Medicines compare to Moderna?

Is MRNA or PRAX more profitable?

Which has stronger earnings & valuation, MRNA or PRAX?

Which has more volatility & risk, MRNA or PRAX?

Do analysts prefer MRNA or PRAX?

Does the media favor MRNA or PRAX?

Do insiders and institutionals have more ownership in MRNA or PRAX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRAX vs. The Competition

Praxis Precision Medicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools